Gregory L. Weaver
Chief Financial OfficerMr. Gregory L. Weaver, also known as Greg, CPA, M.B.A., was Chief Financial Officer of Cognito Therapeutics, Inc. from October 2023 to 2024. He serves as Chief Financial Officer of Altimmune, Inc. since November 11, 2024. He joined Altimmune, Inc. on November 11, 2024. He leads all finance-related and Investor Relations functions at the Company. He was Chief Financial Officer at BioIntellisense, Inc. and served as its Board Member. He is a Board Member of Rejuveron Life Sciences. He was a Member of Executive Board at atai Life Sciences AG since July 2021 until October 2022. He had served as Member of Supervisory Board at TME Pharma N. V. (formerly known as NOXXON Pharma N. V.) since June 24, 2021 until 2022. Mr. Weaver was Supervisory Board Member at atai Life Sciences AG. He had been Chief Financial Officer of Atai Life Sciences N. V. since September 2020 until August 2022. He served as the Chief Financial Officer at Eloxx Pharmaceuticals, Ltd. since September 26, 2017 until March 2020. Mr. Weaver is a seasoned financial executive with experience in leading business and financial operations for private and public companies, including financing transactions, strategic planning, Investor Relations and business development initiatives. Mr. Weaver served as Chief Financial Officer of ProMetic Life Sciences Inc. since November 1, 2015 until August 22, 2017 where he led the Company's global financial team. Mr. Weaver served as Global Chief Financial Officer and Executive Vice President of Oryzon Genomics S. A. from January 12, 2015 to October 2015. He is a senior finance professional with extensive and relevant biopharmaceutical sector experience, both as Chief Financial Officer and Board Director of NASDAQ-listed and private companies, in the fields of drug development, medical devices and drug delivery, with a focus on growth from start-up through IPO, as well as product commercialization and exit strategies. His specialties include: executive financial leadership, Investor Relations, financing transactions, accounting and financial reporting and M&A. Prior to joining ProMetic, Mr. Weaver served as Chief Financial Officer at Oryzon Genomics where he managed the Company's IPO financing. He served as the Chief Financial Officer, Senior Vice President, Treasurer and Corporate Secretary of Fibrocell Science, Inc. from September 2013 to October 2, 2014 and served as its Principal Accounting Officer until October 2, 2014. Mr. Weaver served as the Chief Financial Officer and Senior Vice President at Celsion Corp. from July 8, 2011 to June 30, 2013. He served as the Chief Financial Officer and Senior Vice President of Finance of Poniard Pharmaceuticals, Inc. from February 18, 2009 to August 6, 2010. He served as the Chief Financial Officer and Senior Vice President of Sirna Therapeutics Inc. from February 13, 2006 to December 2006 and also served as its Principal Accounting Officer. Mr. Weaver served as the Chief Financial Officer of Talyst, Inc. from February 2007 to February 2009. He served as the Chief Financial Officer of Marina Biotech, Inc. (also known as Nastech Pharmaceuticals) from May 2002 to September 2005 and Corporate Secretary from 2003 to September 2005 and Principal Accounting Officer until September 2005. He served as Vice President of Marina Biotech, Inc. until September 2005. Mr. Weaver served as a Vice President and Chief Financial Officer of ILEX Oncology Inc. from January 2000 to April 2002 and also served as its Vice President, Strategic Development. He served as Vice President & Chief Financial Officer of Prism Technologies Business from 1996 to 1998. He held increasingly senior positions with Fidelity Capital and Arthur Andersen LLP. He served as the Chief Financial Officer of a division of Fidelity Capital Publishing from 1992 to 1995. He served as an Independent Director of Egalet Corporation since February 5, 2014 until January 31, 2019. He served as an Auditor with Arthur Andersen Co. from 1983 to 1987. He served in the United States Air Force. He had been a Director at Atossa Therapeutics, Inc. (formerly known as Atossa Genetics Inc.) since October 14, 2013 until October 05, 2023 and served as its Chief Financial Officer since June 2023 until October 05, 2023. He served as a Director of Oryzon Genomics S. A. from September 2014 to January 2015. Mr. Weaver served as an Independent Director at Celsion Corp. from June 20, 2005 to July 8, 2011. He served as an Independent Director of SCOLR Pharma Inc. (now known as Nutraceutix Inc.) from October 8, 2007 to March 31, 2009. He is a Member of the Licensing Executive Society. He is a Member of the American Institute of Certified Public Accountants. He served as a Director of Fibrocell Science, Inc. He is a Certified Public Accountant license in 1985. He received an M.B.A. from Boston College and a B.S. in Accounting and Finance from Trinity University.
Positions
- Company NameAltimmune, Inc.Stock CodeALTPositionChief Financial OfficerColleagues
- JBJerome Benedict DursoChairman, CEO & President
- MSM. Scot RobertsChief Scientific Officer
- CAChristophe Arbet-EngelsChief Medical Officer
- RMRichard MenziusoVP, Global Controller & Principal Accounting Officer
- PLPhilip L. HodgesIndependent Director
- WFWayne F. PisanoIndependent Director
- CACatherine Angell SohnIndependent Director
- KOKlaus O. SchaferIndependent Director
